KIMS Hospitals runs a 26-hospital, 8,600+ bed multi-specialty network across five states, and its Q2 FY27 print arrives with revenue growing fast but profitability still weighed down by gestation costs of newly commissioned hospitals. The key things the quarter will speak to are whether finance costs fall as guided after the Rs. 1,500 Cr QIP-funded debt repayment, and whether insurance empanelment completion unlocks ramp-up at Thane, Nashik and the Bangalore assets.
| Results date | November 04, 2026 |
|---|---|
| Quarter | Q2 FY 2026-2027 |
| Previous quarter revenue | Rs. 1,179.5 Cr (+35.3% YoY) |
| Previous quarter PAT | Rs. 37.4 Cr (-56.0% YoY) |
| Previous quarter EBITDA margin | 20.1% (per investor presentation; press release states 17.4%) |
| Market cap | Rs. 29,478.16 Cr |
| CMP | Rs. 701.8 |
The Board of Directors is scheduled to meet on November 4, 2026 to approve the Q2 and half-year FY27 standalone and consolidated financial results. The trading window for designated persons was closed from October 1, 2026.
An IIFL Capital earnings call is scheduled for November 5, 2026 at 10:00 am IST to discuss strategy post the Q2 FY27 results.
The Q2 FY27 print is the first clean test of management's guidance that interest expense reduces from Q2 FY27 onwards, after the Rs. 1,500 Cr QIP funded a Rs. 910 Cr borrowing prepayment in Q1 and debt fell from Rs. 3,250 Cr at the start of FY27 to about Rs. 2,400 Cr in early July.
Volume momentum is the tailwind: Q1 FY27 IP volumes grew 26.6% YoY to 72,493 and OP volumes 28.5% to 6,58,617, with ARPOB at Rs. 47,200 and guided ARPOB growth of 4-5%, while management steers analysts to ARPP (Rs. 1,63,573 in Q1) as the stronger indicator.
The margin story remains dominated by gestation drag — each new large-format hospital loses Rs. 20-30 Cr EBITDA pre-breakeven, and the Kondapur transition duplicates costs for 3-4 months with an impact management flagged as possibly exceeding the Rs. 15-25 Cr range seen in the Sunshine hospital move. Insurance empanelment, the stated primary ramp-up constraint at Thane, Nashik and the Bangalore assets, was guided for completion with key insurers by end-August/mid-September 2026, with 50% of insurers empanelled at the Q1 call date — the Q2 call should confirm where that landed.
The CGHS rate revision carries a guided Rs. 10-12 Cr FY27 EBITDA benefit but with full impact landing in Q4, so little should show in this quarter's P&L. The call is also likely to cover the Bangalore cluster's path to zero EBITDA loss for FY27 against the Rs. (192) Mn Q1 Karnataka loss, and Thrissur commissioning within the stated 3-4 month window from August 2026.
Performance vs guidance tracking: The Q1 FY27 call left a testable guidance stack; Q2 is the first quarter where several items can be checked.
Kondapur ramp and transition costs
October acquisitions and O&M integration
Operating metric trajectory
Risks and governance items to monitor
Consolidated PBT fell 50.2% YoY in Q1 FY27 even as revenue rose 35.3%, and FY26 PAT declined 41.7%, which the annual report attributes to 'initial gestation costs of expansion'. Management said the 4-5 newly commissioned hospitals are yet to break even, with each new large-format hospital incurring an interim EBITDA loss of Rs. 20-30 Cr.
Management guided 4-5% ARPOB growth on the Q1 FY27 call, against the historical 15-16% trend analysts flagged, with the older target of about Rs. 50,000 ARPOB over 8 quarters from Q2 FY26 compared against Rs. 47,200 in Q1 FY27. Management pointed to cancer specialty additions in Andhra Pradesh hospitals supporting future ARPOB and steered analysts to ARPP as the stronger indicator.
Management guided the Mahadevapura facility to quarterly breakeven in Q1 FY27 and Electronic City in Q3 FY27, with the Bangalore cluster targeted at zero EBITDA loss for full year FY27. An analyst flagged that slide 25 still showed a Q1 loss at Mahadevapura, so the Q2 call should reconcile that gap.
KIMS completed a Rs. 1,500 Cr QIP in June 2026 and prepaid Rs. 910 Cr of borrowings in Q1 FY27, taking debt from Rs. 3,250 Cr at the start of FY27 to Rs. 2,570 Cr at June 30 and about Rs. 2,400 Cr in early July. Management guided interest expense reduction from Q2 FY27 onwards, with Rs. 413.51 Cr of QIP proceeds still unutilized.
Management guided existing-hospital occupancy (no new beds) of 65-70% by FY30, with Telangana occupancy targeted at 70% over the next 3-4 years. Reported occupancy of 49.0% in Q1 FY27 reflected renovation beds and late-quarter Kondapur additions; management stated occupancy is 'already at 65% kind of an occupancy' excluding those beds.
Disclaimer: This earnings preview is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.